SCHEMBL1754487

SCHEMBL1754487

CC(C)NC(=O)c1cnn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
HCAR2 Q8TDS4 7/20 0.40
KCNA3 P22001 4/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 1/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
CNR2 P34972 1/20 0.40
NPC1 O15118 3/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PDE2A O00408 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1754478 0.91 RAB9A (0.46) HCAR2KCNA3LMNAALDH1A1RAB9A
SCHEMBL1754247 0.91 PDE2A (0.50) HCAR2LMNAMAPTPDE2AGPR119
SCHEMBL2083973 0.90 CNR1 (0.47) HCAR2ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL2083971 0.90 CNR1 (0.47) HCAR2ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL1753993 0.88 CNR1 (0.40) CNR2PDE2A
SCHEMBL4115722 0.87 CNR2 (0.42) HCAR2LMNARAB9ASMN1; SMN2MAPT
SCHEMBL4129143 0.87 RAB9A (0.42) LMNAALDH1A1KMT2ARAB9ASMN1; SMN2
SCHEMBL2085751 0.87 TACR3 (0.42) HCAR2ALDH1A1KMT2ARAB9ASMN1; SMN2
SCHEMBL4121624 0.86 PDE4A (0.45) HCAR2KCNA3LMNAALDH1A1RAB9A
SCHEMBL4118485 0.86 RAB9A (0.40) HCAR2LMNAALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US claimed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US claimed
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US disclosed
EP-2520577-A1 Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists Mitsubishi Tanabe Pharma Corporation (JP) 2012-11-07 EP disclosed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US disclosed
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US disclosed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR TSHR 40/4885HCAR2 194/4885KCNA3 588/4885
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR TSHR 40/4885HCAR2 187/4885KCNA3 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.